A Phase 2 interventional study of ELX-02 and Ivacaftor in Cystic Fibrosis, sponsored by Eloxx Pharmaceuticals, Inc.. Completed at 9 sites in 3 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2023-08-21.
Sponsored by Eloxx Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Cystic Fibrosis with a site in Israel — 2 open to participants now, 3 under way, 1 of them phase 3. Cystic Fibrosis · Israel.
Among the 62 studies in Cystic Fibrosis with a site in Israel, this one is the 49th largest by enrollment of the 53 interventional ones that give a count, is one of 3 that started in 2019, is one of 10 in phase 2, and was the 50th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →2 of the 62 studies in Cystic Fibrosis with a site in Israel are open now. Recruiting first, the newest first:
SpliSense Ltd. · Sites in Israel, United States, Czechia and 6 more countries
Ages 18+
Rambam Health Care Campus · Sites in Israel
Ages 5+ · Healthy volunteers
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 27 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 121 across the 53 interventional studies, 80 across the 8 observational. Of the 46 that completed or were terminated, 29 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 62 have an industry lead sponsor. The 10 most frequent:
Eloxx Pharmaceuticals, Inc. is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Eloxx Pharmaceuticals, Inc. has 2 studies filed under Cystic Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Cystic Fibrosis with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06429176SpliSense Ltd.Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 62 studies in Cystic Fibrosis with a site in Israel, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 with and without ivacaftor in patients with CF with at least one G542X allele or phenotypically similar nonsense allele.
Up to 16 patients will be enrolled in the trial; up 4 patients will be homozygotes to G542X, and the remaining patients will be compound heterozygotes with G542X or phenotypically similar nonsense mutation and any Class 1 or Class 2 mutation.
Each patient will receive 5 escalating doses as follows:
Patients must meet the following criteria to participate in this study:
Patients with any of the following characteristics/conditions will not be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eukaryotic ribosomal selective glycoside (ERSG)
Drug: ELX-02 · Drug: Ivacaftor
AEs associated with different dose levels of ELX-02
Time frame: From the time of first dosing through the follow-up visit, an average of approximately 9 weeks
Area under the plasma concentration curve from time zero to 24 hours (AUC0-24)
Full PK profile 8 blood samples up to 24 hours
Time frame: Day 1 of treatment periods 1, 2, 3, and 4
Maximum observed plasma concentration (Cmax) on Day 1
Full PK profile 8 blood samples over 24 hours
Time frame: Day 1 of treatment periods 1, 2, 3, and 4
Peak observed plasma concentration (Cpeak) over time
Time frame: Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7, and 14 of treatment period 4, sparse sampling, blood sampling at 30 min and 1 hour post-dose
Trough observed plasma concentrations (Cpredose) over time
Time frame: Days 1, 2 and 7 of treatment periods 1-3, Days 1, 2, 7 and 14 of treatment period 4, sparse blood sampling at pre-dose
Changes from baseline in sweat chloride concentration
Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4
Changes from baseline in percent predicted forced expiratory volume (ppFEV1)
Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4
Changes from baseline in percent predicted forced vital capacity (ppFVC)
Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4
Changes from baseline in percent predicted forced expiratory flow at 25-75% (ppFEF25-75)
Time frame: From baseline to Day 7 of treatment periods 1-3, and Days 7 and 14 of treatment period 4
Ran from Nov 2019 to primary completion in Apr 2022, 29 months.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 29 months is above that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ELX-02
Eloxx Pharmaceuticals, Inc.